Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | POLB | P06746 | 5/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30060749 | 1.00 | MAPT (0.60) | MAPTKDM4EALDH1A1POLBPKM | |
| SCHEMBL13248196 | 0.87 | MAPT (0.52) | MAPTKDM4EALDH1A1POLBPKM | |
| SCHEMBL28933688 | 0.86 | KAT2B (0.49) | MAPTKDM4EALDH1A1POLBPRSS1 | |
| SCHEMBL4427844 | 0.86 | MAPT (0.51) | MAPTKDM4EALDH1A1POLBPKM | |
| SCHEMBL2779876 | 0.85 | MAPT (0.49) | MAPTKDM4EALDH1A1POLBPKM | |
| SCHEMBL29356494 | 0.84 | MAPT (0.42) | MAPTKDM4EALDH1A1POLBPRSS1 | |
| SCHEMBL13583637 | 0.84 | MAPT (0.42) | MAPTKDM4EALDH1A1POLBPRSS1 | |
| SCHEMBL27343040 | 0.82 | MAPT (0.73) | MAPTKDM4EALDH1A1POLBPKM | |
| SCHEMBL596079 | 0.81 | GSTM2 (0.61) | KMT2AMEN1 | |
| SCHEMBL13795300 | 0.81 | GSTM2 (0.61) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11619630-B2 | Immunochromatography device | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2023-04-04 | — | — | US | disclosed |
| US-20200333336-A1 | IMMUNOCHROMATOGRAPHY DEVICE | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2020-10-22 | — | — | US | disclosed |
| CN-111480078-A | Immunochromatographic device | 株式会社三和化学研究所 | 2020-07-31 | — | — | CN | disclosed |
| US-10144849-B2 | Polishing composition and polishing method using the same | FUJIMI INCORPORATED (JP) | 2018-12-04 | — | — | US | disclosed |
| EP-2566334-B1 | CONTROLLED DRUG RELEASE FROM SOLID SUPPORTS | PROLYNX LLC (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-2566335-B1 | CONTROLLED RELEASE OF ACTIVE COMPOUNDS FROM MACROMOLECULAR CONJUGATES | PROLYNX LLC (US) | 2016-06-29 | — | — | EP | disclosed |
| US-8946405-B2 | Controlled release from solid supports | PROLYNX LLC (US) | 2015-02-03 | — | — | US | disclosed |
| US-8754190-B2 | Controlled release from macromolecular conjugates | PROLYNX LLC (US) | 2014-06-17 | — | — | US | disclosed |
| US-8703907-B2 | Controlled drug release from dendrimers | PROLYNX LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20130123461-A1 | CONTROLLED DRUG RELEASE FROM DENDRIMERS | PROLYNX LLC (US) | 2013-05-16 | — | — | US | disclosed |
| US-20090197848-A1 | Synthetic mimics of mammalian cell surface receptors: method and compositions | THE PENN STATE RESEARCH FOUNDATION (US) | 2009-08-06 | — | — | US | disclosed |
| US-20090197848-A1 | Synthetic mimics of mammalian cell surface receptors: method and compositions | THE PENN STATE RESEARCH FOUNDATION (US) | 2009-08-06 | — | — | US | disclosed |
| US-7514400-B2 | Synthetic mimics of mammalian cell surface receptors: method and compositions | THE PENN STATE RESEARCH FOUNDATION (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514400-B2 | Synthetic mimics of mammalian cell surface receptors: method and compositions | THE PENN STATE RESEARCH FOUNDATION (US) | 2009-04-07 | — | — | US | disclosed |
| US-20060229235-A1 | Synthetic mimics of mammalian cell surface receptors: method and compositions | THE PENN STATE RESEARCH FOUNDATION (US) | 2006-10-12 | — | — | US | disclosed |
| US-5614368-A | LABELLED-HAPTEN WITH POLYPEPTIDES FOR DIAGNOSIS OF ANTIGENS AND ANTIBODIES | MOLECULAR DEVICES CORPORATION (US) | 1997-03-25 | — | — | US | disclosed |
| US-5256395-A | Drug delivery by administering a receptor binding assay having a dual preferential monoclonal antibody conjugating with predetermined haptens | IMMUNOTECH PARTNERS (FR) | 1993-10-26 | — | — | US | disclosed |
| US-5180828-A | Proteins and polynucleotides, nondestructive | MOLECULAR DEVICES CORPORATION (US) | 1993-01-19 | — | — | US | disclosed |
| EP-0263046-B1 | AFFINITY ENHANCEMENT IMMUNOLOGICAL REAGENTS FOR DETECTION AND KILLING OF SPECIFIC TARGET CELLS | IMMUNOTECH PARTNERS (FR) | 1992-04-15 | — | — | EP | disclosed |
| EP-0263046-A1 | Affinity enhancement immunological reagents for detection and killing of specific target cells | IMMUNOTECH PARTNERS (FR) | 1988-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123461-A1 | CONTROLLED DRUG RELEASE FROM DENDRIMERS | SLC43A1, SLC47A1, SLC47A2 | MAPT 1847/4885KDM4E 3717/4885ALDH1A1 2780/4885 |
| US-20090197848-A1 | Synthetic mimics of mammalian cell surface receptors: method and compositions | MSR1, M6PR, ASGR1 | MAPT 4740/4885KDM4E 4618/4885ALDH1A1 4719/4885 |
| US-20060229235-A1 | Synthetic mimics of mammalian cell surface receptors: method and compositions | MSR1, M6PR, ASGR1 | MAPT 4740/4885KDM4E 4618/4885ALDH1A1 4719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.